

DI cont.
cells; molecules which inhibit expression of the [CD11d/CD18] integrins or their ligands, and peptides and peptidomimetics derived from the [CD11d/CD18] integrins or their ligands which block the interaction of the [CD11d/CD18] integrins or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis or dependent restenosis of a blood vessel following injury to vascular tissue.

5. (twice amended) The method of claim 1 wherein the [CD11d/CD18] integrin is selected from the group consisting of [Mac-1,] LFA-1 (CD11a/CD18), [and] p150,95 (CD11c/CD18), and CD11d/CD18.

6. (twice amended) The method of claim 5 wherein the [CD11d/CD18] integrin is Mac-1 (CD11b/CD18).

8. (twice amended) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with [CD11d/CD18] the integrins or their ligands and which block the interaction of the [CD11d/CD18] integrins or their ligands with vascular cells[; molecules which inhibit expression of the CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells or tissues].

9. (twice amended) The method of claim 5 wherein the [CD11d/CD18] integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

10. (amended) The method of claim 6 wherein the compound is an antibody or antibody fragment immunoreactive with Mac-1 (CD11b/CD18).
